TrialInternational immunopharmacology2021

Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.

Hong Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.